Skip to main content

Alport Syndrome clinical trials at UC Health
2 in progress, 1 open to eligible people

  • An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

    open to eligible people ages 12-65

    This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.

    at UCLA

  • A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

    Sorry, in progress, not accepting new patients

    This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome. The Phase 2 portion of the trial will be open-label and enroll up to 30 patients. The Phase 3 portion of the trial will be double-blind, randomized, placebo-controlled and will enroll up to 180 patients.

    at UCLA UCSF

Last updated: